Invizius recently announced that it has been awarded a second Biomedical Catalyst grant (Feasibility and Primer Award) by Innovate UK to research a new field of application—peritoneal dialysis (PD)—for its H-Guard technology.
The company is developing a H-Guard haemodialysis priming solution, which comprises a novel protein that lines the inside of the dialysis filter and helps dialysis to take place undetected by the body’s immune system. This suppresses the blood’s foreign body response, preventing a repetitive, hostile inflammatory reaction that increases the risk of complications.
As per an Invizius press release, PD offers considerable benefits to patients—but has a high dropout rate, which has limited its adoption as compared to haemodialysis. One of the main causes of dropout is damage to the peritoneal membrane from chronic exposure to PD solutions, and immune activation is thought to be a key driver here.
The company will now assess in-vitro and in-vivo efficacy of a novel method using its technology for PD and progress thereafter into preclinical development. The project will run for 18 months, according to the release.
Invizius chief technology officer Andy Herbert said: “Our board, which comprises members with significant industry experience, together with key PD opinion leaders, has encouraged us to assess how our H-Guard technology could be applied to minimise peritoneal membrane damage, a key issue for PD therapy.
“We are very pleased to receive this second Biomedical Catalyst grant that will allow us to research ways of addressing this issue alongside our haemodialysis development programme—which is running on track.”